Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand .
Pharvaris N.V.February 26, 2021 GMT
ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced dosing of the first patient in RAPIDe-1, an on-demand Phase 2 study evaluating the efficacy, safety, and pharmacokinetics of PHVS416 in patients with HAE due to C1-Inhibitor Deficiency type 1 and 2.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment .
Pharvaris N.V.February 19, 2021 GMT
ZUG, Switzerland, Feb. 19, 2021 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the presentation of clinical data supporting the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of PHA121 (PHA-022121) for the treatment of hereditary angioedema (HAE) at the 2021 American Academy of Allergy Asthma & Immunology (AAAAI) Virtual Annual Meeting, to be held Feb. 26 through March 1, 2021.
Pharvaris develops drug candidates for a rare and potentially life-threatening genetic condition called HAE and related indications. The company announced the pricing of its upsized initial public offering. The ordinary shares begin trading on the Nasdaq Global Select Market today.
Last November, Pharvaris has closed an oversubscribed $80 million Series C financing bringing its total venture funding to over $160 million to date. The company is now going public at Nasdaq. Prospects look promising. During the week the company was able to upsize its IPO. It was originally planned to offer 6.95 million shares at a proposed midpoint price of $18.00 per share. Today Pharvaris announced the pricing of its upsized initial public offering of 8,270,500 of its ordinary shares at an initial public offering price of $20.00 per share, for total gross proceeds of approximately $165.4 million. In addition, Pharvaris has granted the underwriters a 30-day over-allotment option to purchase up to an a